Champions Oncology, Inc. (CSBR) Fair Value 2026

CSBR · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-10-07, Champions Oncology, Inc. (CSBR) trades at $5.01. QOC: 6.8/10. Value Trap Risk: 26/100 (LOW). 1/13 models active.

Key Facts

Ticker
CSBR
Price
$5.01
Quality Score
6.8/10
Value Trap Risk
26/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give CSBR?

1 Intrinsic Value Models vs. Current Price ($5.01)

Core Models (Unlocked)
Model Fair Value Upside
Scenario · High Conviction
 $0.72 -85.7%

All Models Active

All 1 models are displayed above.

What Is Champions Oncology, Inc. (CSBR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Champions Oncology, Inc.'s intrinsic value is estimated at $0.72. Trading at its current price of $5.01, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -85.7%.

What Do the Models Say About CSBR?

1 of 13 models are currently active for CSBR. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does CSBR Rank in Biotechnology?

Among 622 Biotechnology stocks, CSBR ranks #61 by Quality of Company score. CirclFi's QOC score of 6.8/10 evaluates 32 fundamental signals. A score of 6.8 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

Champions Oncology, Inc.'s positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including breakthrough therapy designations — shape both the opportunity set and risk profile.

Is CSBR a Value Trap?

CirclFi's Value Trap algorithm assigns CSBR a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Champions Oncology, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Champions Oncology, Inc. earns a quality score of 6.8/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CSBR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CSBR's 1 active models, average confidence is 60%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Champions Oncology, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

QTTBQ32 Bio Inc.QOC 6.8VNDAVanda Pharmaceuticals Inc.QOC 6.8TNGXTango Therapeutics, Inc.QOC 6.8XBIOXenetic Biosciences, Inc.QOC 6.8ICCCImmuCell CorporationQOC 6.8OCULOcular Therapeutix, Inc.QOC 6.8IPHAInnate Pharma S.A.QOC 5.5LONALeonaBio, Inc.QOC 4.8PDSBPDS Biotechnology CorporationQOC 4.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: QTTB · VNDA · TNGX · XBIO · ICCC · OCUL · IPHA · LONA · PDSB · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CSBR?

6 companies across all industries closest to CSBR’s Quality of Company score of 6.8/10.

REAXReal REMAX Group Inc.QOC 6.8GOAIEva Live, Inc.QOC 6.8RXORXO, Inc.QOC 6.8OISOil States International, Inc.QOC 6.8DCGODocGo Inc.QOC 6.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: REAX · GOAI · RXO · OIS · DCGO · NVDA

Where Does CSBR Sit in CirclFi's Biotechnology Rankings?

CSBR is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Champions Oncology, Inc.’s Valuation?

What is Champions Oncology, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Champions Oncology, Inc. (CSBR). The Quality of Company score is 6.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CSBR overvalued or undervalued right now?

At $5.01, 0 of 1 active models suggest CSBR may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Champions Oncology, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.8 mean for CSBR?

Champions Oncology, Inc.'s QOC of 6.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CSBR?

CirclFi analyzes CSBR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is CSBR a value trap in 2026?

Champions Oncology, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Champions Oncology, Inc. (CSBR) a Quality of Company score of 6.8/10 across 32 fundamental signals as of 2026-10-07.” Source: circlfi.com/stock/CSBR/ · Methodology
Primary sources for this CSBR valuation
  • Financial statements: Champions Oncology, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000771856) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CSBR as of ; valuations recomputed .